drugset / Trial / NCT02508168
Phase 1 Bioavailability Study of SYR-322MET
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to determine the relative bioavailability of alogliptin 12.5 milligram (mg) and immediate-release metformin 1000 mg when administered as individual tablets and as a fixed-dose combination (FDC) product.
Timeline
- Start
- 2016-04
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alogliptin | Unknown | 12.5 mg | Oral |
| Subject | Metformin | Small molecule | 1000 mg | Oral |
| Subject | SYR-322MET | Unknown | 12.5 mg | Oral |
| Subject | SYR-322MET | Unknown | 1000 mg | Oral |
Indications
No indication recorded.